MJFF funds collaboration to identify toxic proteins on PET scans
Xingimaging and Synusight received a MFJJ grant to develop PET imaging technology that monitors toxic protein clumps in Parkinson's.| Parkinson's News Today
Xingimaging and Synusight received a MFJJ grant to develop PET imaging technology that monitors toxic protein clumps in Parkinson's.| Parkinson's News Today
A $697,000 MJFF grant and a renewed, five-year, $2.7 million NIH award will fund early Parkinson's research at the University of Wisconsin.| Parkinson's News Today
The recipients of this year's grants include scientists and clinicians studying Parkinson’s biology, brain networks, and symptoms.| Parkinson's News Today
Parkinson’s patients and their care partners found several aspects of a personalized fall prevention program effective, despite barriers.| Parkinson's News Today
Seal Rock has joined an MJFF initiative to develop therapies targeting the LRRK2 gene, which can contribute to Parkinson’s development.| Parkinson's News Today
Having metabolic syndrome, a cluster of abnormalities characterized by abdominal obesity and high blood sugar, may increase Parkinson's risk.| Parkinson's News Today
Analyzing real-world patient data may help researchers better understand Parkinson’s causes, its early signs, and responses to therapy.| Parkinson's News Today
ENERGI-F705PD, a potential disease-modifying therapy for Parkinson’s, was found safe and well tolerated in healthy volunteers in a trial.| Parkinson's News Today
In a mouse model of Parkinson’s, continuous exposure to low-oxygen air eased or even reversed motor symptoms and slowed disease progression.| Parkinson's News Today
Insilico said it plans to ask the FDA this year for permission to move an AI-designed Parkinson's therapy into clinical trials.| Parkinson's News Today
Target enrollment is complete for a Phase 1b trial testing the safety and tolerability of GT-02287 in people with Parkinson’s disease.| Parkinson's News Today
The FDA has cleared CAP-003, a gene therapy for Parkinson’s associated with GBA mutations, to be tested in clinical trials.| Parkinson's News Today
Casma Therapeutics will develop CSM-101 as a potential oral treatment for Parkinson's disease and Gaucher disease.| Parkinson's News Today
Blood levels of 2 proteins in REM sleep behavior disorder patients linked with later finding of Parkinson's-like disease, Lewy body dementia.| Parkinson's News Today
Poor hand grip strength was tied to a higher risk of developing Parkinson’s in a U.K. study, especially among those with genetic risk factors.| Parkinson's News Today
While there's no test to confirm a Parkinson's diagnosis in its early stages, the disease can be detected based on a variety of symptoms.| Parkinson's News Today
Parkinson's disease symptoms affect both motor skills and nonmotor skills, and progress differently in each person.| Parkinson's News Today
The American Parkinson Disease Association (APDA) has awarded $2.6 million to research projects aiming to better understand Parkinson's.| Parkinson's News Today
The FDA approved a brain mapping tool that will enable doctors to more precisely use neuromodulation therapies like DBS.| Parkinson's News Today
UCF researchers have developed a biosensor that can rapidly detect and quantify dopamine levels in unprocessed blood samples.| Parkinson's News Today
The clinical trial is assessing the safety of Allyx Therapeutics' ALX-001 versus a placebo when given to adults twice daily for 28 days.| Parkinson's News Today
Learn about Parkinson's disease, a condition that affects the brain, resulting in issues with movement, balance, and more.| Parkinson's News Today
